Two Sigma Advisers LP Has $23.59 Million Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Two Sigma Advisers LP grew its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 65.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 757,700 shares of the company's stock after acquiring an additional 300,200 shares during the quarter. Two Sigma Advisers LP owned 1.51% of Immunocore worth $23,587,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of IMCR. SG Americas Securities LLC boosted its stake in Immunocore by 1,867.3% during the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company's stock valued at $5,435,000 after buying an additional 152,207 shares during the last quarter. Primecap Management Co. CA increased its holdings in Immunocore by 26.7% during the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company's stock valued at $76,954,000 after buying an additional 520,950 shares during the period. Candriam S.C.A. increased its holdings in Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock valued at $10,621,000 after buying an additional 124,417 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in Immunocore during the second quarter valued at approximately $3,686,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Immunocore by 16.2% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company's stock valued at $13,470,000 after acquiring an additional 55,463 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Analyst Ratings Changes

IMCR has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research note on Thursday, October 24th. UBS Group assumed coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a "sell" rating and a $24.00 price objective for the company. Mizuho cut shares of Immunocore from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a report on Monday, October 7th. Finally, Morgan Stanley cut their target price on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $69.18.

Immunocore Stock Performance

Shares of IMCR traded up $0.55 during mid-day trading on Friday, hitting $31.52. The company's stock had a trading volume of 212,301 shares, compared to its average volume of 225,664. The firm has a market capitalization of $1.58 billion, a PE ratio of -33.18 and a beta of 0.73. Immunocore Holdings plc has a one year low of $29.72 and a one year high of $76.98. The stock's 50-day moving average is $32.30 and its two-hundred day moving average is $35.86. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. During the same period in the prior year, the company posted ($0.59) EPS. The company's revenue was up 23.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.